These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11011803)

  • 1. Development of tinzaparin: a heparinase-digested low-molecular-weight heparin.
    Hedner U
    Semin Thromb Hemost; 2000; 26 Suppl 1():23-9. PubMed ID: 11011803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extending the role of antithrombotic agents: an example based on the low-molecular-weight heparin, tinzaparin.
    Hainer JW; Sprogel P; Lindenstroem E
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():3-9. PubMed ID: 15085461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan.
    Maddineni J; Ma Q; Hoppensteadt DA; Demir M; Manoni M; Cornelli U; Fareed J
    Clin Appl Thromb Hemost; 2004 Jan; 10(1):27-37. PubMed ID: 14979402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tinzaparin in the treatment of venous thromboembolism.
    Pineo GF; Hull RD
    Expert Opin Pharmacother; 2003 Dec; 4(12):2355-62. PubMed ID: 14640933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
    Mousa SA
    Cardiovasc Drug Rev; 2002; 20(3):199-216. PubMed ID: 12397367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Caro JJ; Getsios D; Caro I; O'Brien JA
    Pharmacoeconomics; 2002; 20(9):593-602. PubMed ID: 12141887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tinzaparin sodium: a low-molecular-weight heparin.
    Neely JL; Carlson SS; Lenhart SE
    Am J Health Syst Pharm; 2002 Aug; 59(15):1426-36. PubMed ID: 12166042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
    Bara L; Planes A; Samama MM
    Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of low-molecular-weight heparins in orthopedic surgery.
    Lassen MR
    Semin Thromb Hemost; 2000; 26 Suppl 1():53-6. PubMed ID: 11011807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
    Cheer SM; Dunn CJ; Foster R
    Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.
    Friedel HA; Balfour JA
    Drugs; 1994 Oct; 48(4):638-60. PubMed ID: 7528134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tinzaparin as an antithrombotic: an overview.
    Fegan CD
    Hosp Med; 1998 Feb; 59(2):145-8. PubMed ID: 9797891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
    Hiebert LM
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
    Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
    Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.
    Jara-Palomares L; Solier-Lopez A; Elias-Hernandez T; Asensio-Cruz M; Blasco-Esquivias I; Marin-Barrera L; de la Borbolla-Artacho MR; Praena-Fernandez JM; Montero-Romero E; Navarro-Herrero S; Serrano-Gotarredona MP; Sánchez-Díaz JM; Palacios C; Otero R
    Thromb Res; 2017 Sep; 157():90-96. PubMed ID: 28719850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of LMWH (tinzaparin) on coagulation and fibrinolytic activation in pregnant women at risk of thrombosis.
    Yoneda M; Brosnan JF; Norris LA; Bonnar J
    Thromb Res; 2006; 117(3):283-90. PubMed ID: 15869785
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy.
    Ní Ainle F; Wong A; Appleby N; Byrne B; Regan C; Hassan T; Milner M; Sullivan AO; White B; O'Donnell J
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):689-92. PubMed ID: 18832911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
    Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
    Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: ischemic priapism secondary to tinzaparin.
    Purnell J; Abdulla AN
    Int J Impot Res; 2018 Apr; 30(2):62-64. PubMed ID: 29222429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.